REC-4881's FAP efficacy data sets up a registrational pathway discussion with FDA — the outcome of that alignment defines whether RXRX has its first approvable asset

Bull

A positive outcome would be FDA alignment on an accelerated approval pathway using polyp burden reduction as a surrogate endpoint, with a registrational study design that Recursion can execute within its current cash runway through 2027. Specifically, FDA accepting the existing Phase 2 data package — median 43% polyp burden reduction at Week 13 deepening to 53% at Week 25, with 40% of patients improving Spigelman stage — as sufficient to anchor a confirmatory trial design would validate the asset's approvability and materially de-risk the pipeline. This outcome would establish REC-4881 as a credible near-term commercial asset and validate Recursion's AI-enabled drug discovery platform with its first potential regulatory milestone.

Bear

The most likely disappointment scenario is FDA declining to accept polyp burden reduction as an approvable surrogate endpoint and instead requiring a hard clinical endpoint — such as reduction in colorectal cancer incidence or surgical intervention rates — making a registrational trial impractically large and long given Recursion's runway. A second failure mode is FDA requesting a randomized controlled trial with a substantially larger patient population than the existing TUPELO cohort supports, given the small evaluable sample size (n=12 for the primary efficacy analysis), which would strain the company's capital position and extend the development timeline beyond the 2027 cash runway.